Patents Assigned to IMMUTEP
  • Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
    Patent number: 10232038
    Abstract: The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: March 19, 2019
    Assignee: IMMUTEP
    Inventor: Frederic Triebel
  • COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3
    Publication number: 20180340025
    Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: July 28, 2016
    Publication date: November 29, 2018
    Applicants: Novartis AG, Immutep S.A.S.
    Inventors: Glenn Dranoff, Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to LAG-3 and uses thereof
    Patent number: 9908936
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 6, 2018
    Assignees: Novartis AG, Immutep S.A.S.
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE
    Publication number: 20170119876
    Abstract: The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Applicant: IMMUTEP
    Inventor: Frederic TRIEBEL
  • Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
    Patent number: 9579382
    Abstract: The present disclosure relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: February 28, 2017
    Assignee: IMMUTEP
    Inventor: Frédéric Triebel
  • Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
    Patent number: 9244059
    Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: January 26, 2016
    Assignees: Immutep Parc Club Orsay, Inserm—Institut National De La Sante Et De La Recherche Medicale
    Inventors: Frederic Triebel, Bernard Vanhove, Thomas Haudebourg
  • Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
    Patent number: 8425897
    Abstract: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: April 23, 2013
    Assignee: Immutep S.A.
    Inventors: Karin Jooss, Betty Li, Frederic Triebel
  • CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE
    Publication number: 20110070238
    Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.
    Type: Application
    Filed: June 25, 2010
    Publication date: March 24, 2011
    Applicants: IMMUTEP PARC CLUB ORSAY, INSERM - INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: FREDERIC TRIEBEL, BERNARD VANHOVE, THOMAS HAUDEBOURG
  • USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE
    Publication number: 20110008331
    Abstract: The present disclosure relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Application
    Filed: October 3, 2008
    Publication date: January 13, 2011
    Applicant: IMMUTEP
    Inventor: Frédéric Triebel
  • APC ACTIVATORS IN COMBINATION WITH A CYTOKINE-SECRETING CELL AND METHODS OF USE THEREOF
    Publication number: 20090130054
    Abstract: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
    Type: Application
    Filed: August 29, 2008
    Publication date: May 21, 2009
    Applicants: Cell Genesys, Inc., Immutep S.A.
    Inventors: Karin Jooss, Betty Li, Frederic Triebel